Miguel A. Vences

Dr. Miguel A. Vences

Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
MQMuhammad M. Qureshi
Muhammad M. Qureshi
PKPiers Klein
Piers Klein
HYHiroshi Yamagami
Hiroshi Yamagami
RMRobert Mikulik
Robert Mikulik
TRthe SVIN COVID-19 Global Stroke Registry
the SVIN COVID-19 Global Stroke Registry
Background and Objectives Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), IVT, and mechanical thrombectomy over a 1-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020). Methods We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, IVT treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 148,895 stroke admissions in the 1 year immediately before compared with 138,453 admissions during the 1-year pandemic, representing a 7% decline (95% CI [95% CI 7.1–6.9]; p < 0.0001). ICH volumes declined from 29,585 to 28,156 (4.8% [5.1–4.6]; p < 0.0001) and IVT volume from 24,584 to 23,077 (6.1% [6.4–5.8]; p < 0.0001). Larger declines were observed at high-volume compared with low-volume centers (all p < 0.0001). There was no significant change in mechanical thrombectomy volumes (0.7% [0.6–0.9]; p = 0.49). Stroke was diagnosed in 1.3% [1.31–1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82–2.97], 5,656/195,539) of all stroke hospitalizations. Discussion There was a global decline and shift to lower-volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared with the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year. Trial Registration Information This study is registered under NCT04934020.

1 September 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
VPVirginia A. Pujol-Lereis
Virginia A. Pujol-Lereis
AFAlan Flores
Alan Flores
MBMiguel A. Barboza
Miguel A. Barboza
CACarlos Abanto-Argomedo
Carlos Abanto-Argomedo
PAPablo Amaya
Pablo Amaya
SASebastián F. Ameriso
Sebastián F. Ameriso

31 July 2021 in Medwave
Verified
Journal Article
Open access
Miguel A. VencesMiguel A. Vences
Miguel A. Vences
JPJuan J Pareja-Ramos
Juan J Pareja-Ramos
POPaula Otero
Paula Otero
LVLiz E Veramendi-Espinoza
Liz E Veramendi-Espinoza
MVMelissa Vega-Villafana
Melissa Vega-Villafana
JZJessica H Zafra-Tanaka
Jessica H Zafra-Tanaka
Objectives To describe and assess clinical characteristics and factors associated with mortality in adult patients with COVID-19 admitted to a national referral hospital in Peru. Methods We conducted a prospective cohort study that included hospitalized patients older than 18 years with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Patients with a positive rapid serological test on admission but no respiratory symptoms nor compatible images were excluded. We collected the data from clinical records. Results A total of 813 adults were included, 544 (66.9%) with confirmed COVID-19. The mean age was 61.2 years (standard deviation: 15.0), and 575 (70.5%) were male. The most frequent comorbidities were hypertension (34.1%) and obesity (25.9%). On admission, the most frequent symptoms were dyspnea (82.2%) and cough (53.9%). A total of 114 (14.0%) patients received mechanical ventilation, 38 (4.7%) were admitted to the intensive care unit, and 377 (46.4%) died. The requirement for ventilatory support, greater lung involvement, and inflammatory markers were associated with higher mortality. It was found that for every 10-year age increase, the risk of dying increased 32% (relative risk: 1.32; 95% confidence interval: 1.25 to 1.38). Those who were admitted to the intensive care unit and were placed on mechanical ventilation had 1.39 (95% confidence interval: 1.13 to 1.69) and 1.97 (95% confidence interval: 1.69 to 2.29) times the risk of dying compared to those who did not, respectively. Conclusion We found a high mortality rate among hospitalized patients associated with older age, higher inflammatory markers, and greater lung involvement.

1 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Miguel A. VencesMiguel A. Vences
Miguel A. Vences
DCDiego Canales
Diego Canales
MAMaria Fe Albujar
Maria Fe Albujar
EBEbelin Barja
Ebelin Barja
MAMary M. Araujo-Chumacero
Mary M. Araujo-Chumacero
DUDiego Urrunaga-Pastor
Diego Urrunaga-Pastor
We describe the case of a 72-year-old man who received the first dose of the BNT162b2 (COMIRNATY) vaccine against COVID-19 on 18 May 2021, and the second dose on 9 September 2021. One day after receiving the first dose, he cursed with malaise, headache, fever, confusion, aggressiveness, and gait alterations. We performed serum and cerebrospinal fluid (CSF) tests (finding elevated proteins in CSF) with negative results for infectious, systemic, and neoplastic causes. We performed brain nuclear magnetic resonance imaging (MRI), finding circumscribed encephalitis at the anterior frontal and bilateral temporal lobes. We were unable to perform a panel of antineuronal antibodies. The patient was readmitted due to early clinical relapse four days after receiving his second dose. We found sequelae lesions at the frontal level but with new demyelinating lesions at the left temporal level in brain MRI. We indicated methylprednisolone, and he presented a favorable improvement. We report an encephalitis case of probable autoimmune etiology after vaccination with BNT162b2, which presented early clinical relapse after receiving the second dose and presented a favorable response to methylprednisolone.

27 March 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
CRClaudio Rodríguez-Fernández
Claudio Rodríguez-Fernández
PRPedro Ruiz-Garcia
Pedro Ruiz-Garcia
MGMaria Jesús Garcia-Sanchez
Maria Jesús Garcia-Sanchez
MMMartiel Manrique-Zegarra
Martiel Manrique-Zegarra
CTCarlos Toledano-Illán
Carlos Toledano-Illán
JPJosé Manuel Pumar
José Manuel Pumar
Background: Long-term follow-up of cerebral aneurysms treated with the Silk Vista Baby (SVB) flow diverter is lacking. This study aimed to assess the technical success, procedural safety, and efficacy of the SVB (Balt, Montmorency, France) for the treatment of intracranial aneurysms in small cerebral vessels over a mid-to long-term follow-up.Methods: We retrospectively analyzed a prospectively maintained database of patients treated with the SVB between September 2018 and June 2021. Data regarding patient demographics, aneurysm characteristics, and technical procedures were also collected. Angiographic and clinical findings were recorded during the procedure and over a period of at least 12 months.Results: Angiographic and clinical follow-up data were available for 50 patients/50 aneurysms. The procedural complication rate was 8%. At 12 months, the final results showed a technical success rate of 100%, the re rupture rate was 0%, neuromorbidity and mortality rates of 4 and 0%, respectively, and an almost complete occlusion rate of 94%.Conclusion: Treatment of complex intracranial aneurysms with the SVB was safe and effective. Long-term results showed high rates of adequate and stable occlusions.

14 November 2022 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Miguel A. VencesMiguel A. Vences
Miguel A. Vences
MAMary M. Araujo-Chumacero
Mary M. Araujo-Chumacero
ECEdu Cardenas
Edu Cardenas
DCDiego Canales
Diego Canales
AAArturo Alvarez
Arturo Alvarez
DUDiego Urrunaga-Pastor
Diego Urrunaga-Pastor
Background: Vaccination is an important public health strategy; however, many neurological adverse effects are associated with COVID-19 vaccination, being encephalitis a rare manifestation. Case presentation: We present the case of a 33-year-old woman who received the first dose of the BBIBP-CorV vaccine against COVID-19 on April 4 and the second dose on April 28, 2021. Three days after receiving the second dose, she experienced a subacute episode of headache, fever, insomnia, and transient episodes of environment disconnection. We obtained negative results for infectious, systemic, and oncological causes. Brain magnetic resonance imaging showed lesions in the bilateral caudate nucleus and nonspecific demyelinating lesions at the supratentorial and infratentorial compartments. The results of the neuronal autoantibodies panel were negative. She had an adequate response to immunoglobulin and methylprednisolone; however, she experienced an early clinical relapse and received a new cycle of immunosuppressive treatment followed by a satisfactory clinical evolution. Conclusions: We report the first case of severe encephalitis associated with BBIBP-CorV (Sinopharm) vaccination in Latin America. The patient had atypical imaging patterns, with early clinical relapse and a favorable response to corticosteroid therapy.